Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.59 |
| ▸ | AR | P10275 | 4/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brofoxine SCHEMBL29710912 | 1.00 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| Brofoxine SCHEMBL4166335 | 0.87 | PGR (0.68) | PGRARNR3C1NR3C2 | |
| SCHEMBL15210358 | 0.86 | PGR (0.48) | PGRARNR3C1NR3C2 | |
| SCHEMBL3870385 | 0.84 | PGR (0.71) | PGRARNR3C1NR3C2 | |
| SCHEMBL5516094 | 0.81 | LMNA (0.42) | PGRARNR3C1NR3C2 | |
| SCHEMBL3295805 | 0.81 | PGR (0.60) | PGRARNR3C1NR3C2 | |
| SCHEMBL3377467 | 0.81 | PGR (0.60) | PGRARNR3C1NR3C2 | |
| SCHEMBL28749684 | 0.81 | PGR (0.50) | PGR | |
| SCHEMBL12649317 | 0.79 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| SCHEMBL3380231 | 0.79 | PGR (0.59) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-8129523-B2 | Coupling process for generating reactive boron-containing derivatives of N-substituted pyrrole-2-carbonitriles to produce biaryls | WYETH LLC (US) | 2012-03-06 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| US-20090054663-A1 | COUPLING PROCESS FOR GENERATING REACTIVE BORON-CONTAINING DERIVATIVES OF N-SUBSTITUTED PYRROLE-2-CARBONITRILES TO PRODUCE BIARYLS | WYETH (US) | 2009-02-26 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050272702-A1 | Coupling process for generating reactive boron-containing derivatives of N-substituted pyrrole-2-carbonitriles to produce biaryls | WYETH (US) | 2005-12-08 | — | — | US | claimed |
| WO-2005105817-A2 | COUPLING PROCESS FOR GENERATING REACTIVE BORON CONTAINING DERIVATIVES OF N-SUBSTITUTED PYRROLE-2 CARBONITRILES TO PRODUCE BIARYLS | WYETH (US) | 2005-11-10 | — | — | WO | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1221844-A2 | SELECTIVE HERBICIDES BASED ON PYRIMIDINE-DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2002-07-17 | — | — | EP | claimed |
| WO-2001024633-A2 | SELECTIVE HERBICIDES BASED ON PYRIMIDINE-DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054663-A1 | COUPLING PROCESS FOR GENERATING REACTIVE BORON-CONTAINING DERIVATIVES OF N-SUBSTITUTED PYRROLE-2-CARBONITRILES TO PRODUCE BIARYLS | BOLA2; BOLA2B, BRI3BP, BROX | PGR 1401/4885AR 3276/4885NR3C1 2069/4885 |
| US-20050272702-A1 | Coupling process for generating reactive boron-containing derivatives of N-substituted pyrrole-2-carbonitriles to produce biaryls | BOLA2; BOLA2B, BRI3BP, BROX | PGR 1401/4885AR 3276/4885NR3C1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.